



NormOxys Secures Series B Financing

BOSTON, MA –April, 22, 2009 – NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs, which enhance the body’s ability to deliver oxygen to diseased cells, today announced that it has secured the first tranche of \$4.5 million in Series B financing. Index Ventures of Geneva, Switzerland led the round with participation from other existing investors.

Proceeds from the financing will be used to advance NormOxys’ preclinical and clinical development of a new class of small molecule drugs, oxyrens, which are a new class of drugs being developed by NormOxys to treat a broad range of diseases where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues. Potential clinical indications include cancer, cardiovascular diseases, anemia, Alzheimer’s’ disease, stroke and diabetic retinopathy. This new financing is in addition to the company securing a Series A financing in August of 2007 of \$8 million.

"We believe this Series B investment and the high quality investors involved validate the premise of NormOxys’ innovative and unique approach to developing a new class of drugs that will deliver oxygen to diseased tissues," said Conrad Bletzer, Jr., Esq., NormOxys President and Co-Founder.

The NormOxys board of directors includes Jean-Pierre Garnier, PhD, Chairman of the NormOxys Board of Directors; Claude Nicolau, PhD, NormOxys Chief Scientific Officer and Co-Founder; Jean-Marie Lehn, PhD, Nobel Laureate in Chemistry and NormOxys Co-Founder; Conrad Bletzer, Jr., Esq., NormOxys President and Co-Founder.; and Drs. Francesco De Rubertis and Michele Ollier of Index Ventures.

About NormOxys

NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues, such as cancer, cardiovascular diseases, anemia, Alzheimer’s’ disease, stroke and diabetic retinopathy. The company is based in Boston, MA and was founded by Prof. Claude Nicolau, PhD, and Nobel Laureate Prof. Jean-Marie Lehn, PhD, based on their groundbreaking investigations in chemistry and cellular biophysics. To learn more about NormOxys, please visit the Company’s website at www.normoxys.com